Benzyl 2-[[3-hydroxy-2-(phenylmethoxycarbonylamino)butanoyl]-methylcarbamoyl]-2-methylpyrrolidine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Benzyl 2-[[3-hydroxy-2-(phenylmethoxycarbonylamino)butanoyl]-methylcarbamoyl]-2-methylpyrrolidine-1-carboxylate
• 英文别名: benzyl 2-[[3-hydroxy-2-(phenylmethoxycarbonylamino)butanoyl]-methylcarbamoyl]-2-methylpyrrolidine-1-carboxylate
• 化学式: C₂₇H₃₃N₃O₇
• 分子量: 511.6
• InChiKey: PMNAJYDWWXAWNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• NMDA receptor modulators and uses thereof
  申请人：Northwestern University

  公开号：US10906913B2

  公开（公告）日：2021-02-02

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorder such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  所公开的化合物在调节 NMDA 受体活性方面具有更强的效力。这些化合物可用于治疗疾病和紊乱，如学习、认知活动和镇痛，特别是减轻和/或减少神经性疼痛。此外，还公开了这些化合物的口服制剂和其他药学上可接受的给药形式，包括静脉注射制剂。
• METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, OR OTHER DISORDERS
  申请人：Northwestern University

  公开号：US20170049845A1

  公开（公告）日：2017-02-23

  The disclosure relates, at least in part, to methods of treating autism in a patient in need thereof by administering an effective amount of a disclosed compound, e.g., a NMDA receptor glycine site partial agonist.
• NMDA RECEPTOR MODULATORS AND USES THEREOF
  申请人：Northwestern University

  公开号：US20190077807A1

  公开（公告）日：2019-03-14

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorder such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.